RDY:NYE-Dr. Reddy's Laboratories Ltd (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 15.86

Change

0.00 (0.00)%

Market Cap

USD 7.45B

Volume

1.46M

Analyst Target

USD 47.58
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Dr Reddy's Laboratories Ltd together with its subsidiaries is engaged in manufacturing of pharmaceutical products. It operates through three segments; Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-28 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 74.37B
HLN Haleon plc

N/A

USD 44.13B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 42.24B
CTLT Catalent Inc

N/A

USD 11.52B
ELAN Elanco Animal Health

N/A

USD 5.75B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 3.59B
BHC Bausch Health Companies Inc

N/A

USD 2.75B
CPHI China Pharma Holdings Inc

N/A

USD 3.69M
YCBD cbdMD Inc

N/A

USD 1.96M
PBH Prestige Brand Holdings Inc

N/A

N/A

ETFs Containing RDY

EMSD 0.03 % 0.00 %

N/A

N/A
BICK 0.00 % 0.64 %

N/A

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
PPEM PortfolioPlus Emerging Ma.. 0.00 % 0.00 %

N/A

USD 1.04M
ZID:CA BMO MSCI India ESG Leader.. 0.00 % 0.69 %

N/A

CAD 0.38B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.97% 60% D- 70% C-
Dividend Return 4.13% 67% D+ 59% D-
Total Return 18.10% 60% D- 72% C
Trailing 12 Months  
Capital Gain 13.97% 60% D- 70% C-
Dividend Return 4.13% 67% D+ 59% D-
Total Return 18.10% 60% D- 72% C
Trailing 5 Years  
Capital Gain 94.60% 93% A 86% B+
Dividend Return 21.48% 80% B- 68% D+
Total Return 116.08% 93% A 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 8.98% 67% D+ 62% D
Dividend Return 10.29% 60% D- 60% D-
Total Return 1.31% 67% D+ 32% F
Risk Return Profile  
Volatility (Standard Deviation) 24.99% 67% D+ 44% F
Risk Adjusted Return 41.19% 73% C 56% F
Market Capitalization 7.45B 70% C- 88% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 46.60 89% 43%
Price/Book Ratio 3.56 40% 26%
Price / Cash Flow Ratio 0.29 70% 79%
Price/Free Cash Flow Ratio 12.28 50% 39%
Management Effectiveness  
Return on Equity 19.27% 90% 83%
Return on Invested Capital 19.02% 90% 87%
Return on Assets 10.40% 90% 94%
Debt to Equity Ratio 1.35% 89% 92%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.